Mesoblast appoints new director
Mesoblast (ASX:MSB) has appointed former Roche Pharmaceuticals CEO William M Burns to its board as a non-executive director.
Burns was CEO of the Roche division from 2005-2009 and also served as a non-executive director on the Roche board between 2010 and this year.
He also serves on the board of Genentech, Chugai Pharmaceutical and Shire.
“Regenerative medicine has the potential to make a major impact on the way serious medical diseases are treated,” Burns commented. “Mesoblast is the global leader in the development of adult stem cell therapies and I am delighted to join this exciting company.”
Mesoblast recently reported its results for the first half of FY14, revealing it ended the period with a cash balance of $250.3 million despite an 11% higher net loss of $30.8 million.
Last month, the company secured a European patent covering use of its mesenchymal precursor cells (MPCs) in cardiac and vascular conditions.
Mesoblast (ASX:MSB) shares were trading 1.04% higher at $5.81 as of around 1.30 pm on Monday.
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...
